Last updated: July 7, 2026
- Typical structure: Astellas asserts one or more Orange Book-listed patents tied to Xtandi and Hospira responds with infringement challenges and invalidity/non-infringement defenses consistent with ANDA litigation.
What products are at issue?
- Brand (reference listed drug): Xtandi (enzalutamide)
- Accused product: Hospira’s proposed generic enzalutamide, tied to an ANDA submission (specific ANDA number not provided).
Where is the case pending?
- Court: U.S. District Court for the District of Delaware
- Case number: 1:18-cv-01675-CFC-CJB
Key litigation components that determine business impact
Without the docket record details (complaint, asserted patent list, ANDA details, claim-by-claim infringement positions, and claim constructions), the analysis that follows cannot be completed at the patent-estate level. The business-critical fields normally derived from the docket are:
Asserted patents and claim scope
- Patent numbers asserted by Astellas
- Whether infringement allegations target composition, formulation, method-of-use, or manufacturing claims
- Independent and dependent claim mapping to Hospira’s proposed labeling and formulation
Validity defenses
- Anticipation/obviousness prior art asserted by Hospira
- Statutory bars (35 USC 102/103) and non-statutory obviousness theories
- Indefiniteness and enablement arguments under 35 USC 112 (where raised)
- Written description / best mode challenges where applicable
Procedural posture that drives launch timing
- Motions to dismiss (including for pleading sufficiency in ANDA cases)
- Claim construction order dates
- Summary judgment outcomes
- Final judgment and any appeal
- Injunction status, if any, tied to specific patents
How does this litigation affect generic entry risk for Hospira?
In ANDA patent cases, the practical risk for the generic company is driven by:
- Whether any asserted patent survives dispositive motions
- Whether infringement is found (or settlements are reached that enable early launch)
- Whether the court’s construction narrows or broadens claim coverage
- Any stay or injunction tied to the asserted patents
At present, the case outcome, settlement posture, and which patents control exclusivity or trigger launch barriers cannot be determined from the information provided.
How does the Astellas vs Hospira dispute compare with typical enzalutamide generic challenges?
Enzalutamide patent estates often include:
- Composition/formulation patents (capsule composition and/or manufacturing)
- Method-of-use patents (treatment regimens in specific disease states)
- Husbandry and process patents (manufacturing methods, crystallinity/particle properties, if claimed)
But without the asserted patent list and claim terms from this docket, it is not possible to map this case to the correct subset of the Xtandi patent estate.
What is the likely patent landscape behind this case?
Orange Book listing driven
This litigation is usually tethered to Xtandi Orange Book-listed patents. In an ANDA case, Astellas’ complaint typically asserts infringement of those listed patents and alleges Hospira’s ANDA submission included a Paragraph IV certification.
What patents protect Xtandi (enzalutamide) in general?
Astellas’ Xtandi estate is commonly comprised of patents that cover:
- Drug substance and/or composition of matter
- Solid oral dosage form characteristics
- Method-of-use claims for specific clinical populations and combinations
- Manufacturing/process claims related to preparing enzalutamide formulations
A precise, litigation-grade breakdown by patent number, assignee, filing date, priority, expiration, and legal status requires docket access.
What does the docket number imply about the litigation schedule?
The caption (CFC-CJB) indicates standard Delaware judge assignment for patent cases. The case number alone does not provide:
- complaint filing date
- service and answer dates
- motion schedule
- claim construction orders
- expert schedules
- dispositive motion outcomes
- trial dates (if any)
- settlement or dismissal dates
Those details are necessary to quantify impact on launch timing.
Litigation outcomes: what can be concluded from the identifier provided?
No dispositive outcome can be stated without record data:
- Whether Astellas obtained an injunction or a final infringement judgment
- Whether the court invalidated all asserted claims
- Whether the parties settled (common in ANDA cases)
- Whether any stay of approval or launch was entered and on what patents
Key takeaways
- The case Astellas US LLC v. Hospira, Inc. (1:18-cv-01675-CFC-CJB) is an ANDA-driven Hatch-Waxman patent infringement action tied to Xtandi (enzalutamide).
- Business conclusions that require patent-level data (asserted patent numbers, claims-in-suit, constructions, validity outcomes, injunction/settlement terms, and effective launch date impacts) are not available from the docket identifier alone.
- A litigation-grade analysis must pull the complaint’s asserted patent list and the court orders that resolve infringement/validity.
FAQs
1) Which Xtandi patents were asserted in 1:18-cv-01675-CFC-CJB?
Not determinable from the docket identifier alone.
2) Was Hospira’s ANDA challenge in this case a Paragraph IV certification?
The case is consistent with Hatch-Waxman ANDA litigation, but the specific certification type is not stated in the information provided.
3) Did the court enter a claim construction order, and which claim terms controlled infringement?
Not determinable without docket orders.
4) Was there a settlement that allowed Hospira to launch enzalutamide before patent expiry?
Settlement status is not determinable from the information provided.
5) What is the effective impact of this case on generic enzalutamide launch timelines in the US?
The effective impact depends on outcomes on the asserted patents, which are not available from the docket identifier alone.
References
- U.S. District Court for the District of Delaware. Case: Astellas US LLC v. Hospira, Inc., 1:18-cv-01675-CFC-CJB.
